摘要
目的分析2005～2009年期间本院应用重组组织型纤溶酶原激活剂(rt-PA)和尿激酶(UK)静脉溶栓治疗患者的院内死亡发生情况。方法对应用rt-PA或UK溶栓治疗的ST段抬高的急性心肌梗死患者(n=57)和肺血栓栓塞症患者(n=60)的溶栓剂应用情况、死亡原因等进行回顾分析研究。结果117例接受溶栓治疗的患者院内死亡10例(8.5%),原因为心源性休克(6例)、心脏破裂(3例)和心室颤动(1例)。10例死亡患者中,无1例因出血并发症死亡;7例为ST段抬高的急性心肌梗死患者,肺血栓栓塞症患者因心源性休克死亡3例。应用rt-PA溶栓治疗的98例(84%)患者院内死亡7例,19例患者接受UK溶栓治疗,死亡3例。结论接受溶栓治疗患者的院内死因主要与基础疾病相关,科学规范的应用溶栓治疗是安全的。
Objective To study the in-hospital mortality rate of recombinant human tissue-type plasrninogen activator（rt-PA） and urokinase（UK） from 2005 to 2009.Methods We retrospectively analyzed the type of thrombolytic agents and cause of death in ST elevated acute myocardial infarctiong patients（n=57） and pulmonary thromboembolism patients（n=60）.Results In the 117cases,ten patients died in hospital due to cardiac shock（n=6）、cardiac rupture（n=3） and ventricular fibrillation（n=1）.No case died of bleeding complication.Seven of ten deaths suffered acute myocardial infarction.The other 3 deathes due to cardiac shock suffered pulmonary thromboembolism.About 84%（98 cases） patients used rt-PA,of whom seven patients died.In the patients using UK（n=19）,3 cases died.Conclusion The in-hospital mortality rate of the patients using thrombolytic therapy was mainly associated with underlying diseases.The scientific and standardized thrombolytic therapy is safe.
出处
《中国药物警戒》
2010年第5期286-288,共3页
Chinese Journal of Pharmacovigilance
基金
国家"十一五"科技重大专项(2008ZX09312-018)
关键词
重组组织型纤溶酶原激活剂
尿激酶
院内死亡率
recombinant human tissue-type plasrninogen activator
urokinase
in-hospital mortality rate
